LifeVantage (LFVN) Aperçu de l'action
LifeVantage Corporation se consacre à l'identification, à la recherche, au développement, à la formulation et à la vente d'activateurs nutrigénomiques avancés, de compléments alimentaires, de nootropiques, de produits de gestion du poids, de pré et pro-biotiques et de produits de soins de la peau et des cheveux à l'échelle internationale. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 0/6 |
| Performances passées | 1/6 |
| Santé financière | 6/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
LFVN Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LifeVantage Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$6.93 |
| Plus haut sur 52 semaines | US$15.00 |
| Plus bas sur 52 semaines | US$3.90 |
| Bêta | 0.55 |
| Variation sur 1 mois | 36.42% |
| Variation sur 3 mois | 48.39% |
| Variation sur 1 an | -48.17% |
| Variation sur 3 ans | 50.65% |
| Variation sur 5 ans | -12.94% |
| Évolution depuis l'introduction en bourse | -71.71% |
Nouvelles et mises à jour récentes
Recent updates
LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential
Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking AlphaShareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...
New Initiatives Will Drive MindBody GLP-1 System's Future Success
Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04
LifeVantage Corporation's ( NASDAQ:LFVN ) investors are due to receive a payment of $0.04 per share on 17th of March...LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LifeVantage Corporation ( NASDAQ:LFVN ) shareholders, with the stock dropping 10% to...LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity
Summary LifeVantage Corporation's Q2 FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%. While the current expense headwinds are expected to abate going into FY2026, I have lowered Adjusted EBITDA estimates and reduced my price target from $31 to $27. While investor disappointment is understandable, I consider the post-earnings sell-off a buying opportunity. That said, with the story being largely tied to the persistent success of a single blockbuster product, the investment thesis is not without risks. Read the full article on Seeking AlphaLifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump
Despite an already strong run, LifeVantage Corporation ( NASDAQ:LFVN ) shares have been powering on, with a gain of 33...What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?
LifeVantage Corporation ( NASDAQ:LFVN ), is not the largest company out there, but it led the NASDAQCM gainers with a...Rendement pour les actionnaires
| LFVN | US Personal Products | US Marché | |
|---|---|---|---|
| 7D | 31.7% | 5.0% | 1.2% |
| 1Y | -48.2% | -15.2% | 28.7% |
Rendement vs Industrie: LFVN a sous-performé le secteur US Personal Products qui a rapporté -15.2 % au cours de l'année écoulée.
Rendement vs marché: LFVN a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| LFVN volatility | |
|---|---|
| LFVN Average Weekly Movement | 11.6% |
| Personal Products Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: Le cours de l'action de LFVN a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de LFVN ( 12% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 235 | Michael Beindorff | www.lifevantage.com |
LifeVantage Corporation se consacre à l'identification, à la recherche, au développement, à la formulation et à la vente d'activateurs nutrigénomiques avancés, de compléments alimentaires, de nootropiques, de produits de gestion du poids, de pré-biotiques et de pro-biotiques, ainsi que de produits de soins de la peau et des cheveux à l'échelle internationale. Elle propose Protandim, un complément alimentaire ; LifeVantage Omega+, un complément alimentaire qui combine les acides gras oméga-3 et oméga-7 DHA et EPA et la vitamine D3 ; LifeVantage ProBio, un complément alimentaire pour soutenir la santé intestinale ; LifeVantage IC Bright, un complément pour soutenir la santé des yeux et du cerveau, réduire la fatigue oculaire, soutenir les fonctions cognitives et favoriser un sommeil normal ; LifeVantage Daily Wellness, un complément alimentaire pour renforcer la santé immunitaire ; LifeVantage Rise AM et Reset PM System qui fournit à l'organisme les nutriments adéquats ; LifeVantage D3+, un complément alimentaire qui apporte de la vitamine D3 et K2, du magnésium, du calcium et d'autres oligo-éléments pour soutenir un système immunitaire équilibré, des os solides et la santé cardiovasculaire ; PhysIQ Fat Burn pour soutenir la gestion du poids ; PhysIQ Prebiotic est un complément alimentaire conçu pour soutenir les bonnes bactéries dans l'intestin et un microbiome sain ; MindBody GLP-1 System, un complément alimentaire qui combine deux produits, MB Core et MB Enhance, conçus pour favoriser la gestion du poids et le bien-être en activant naturellement le GLP-1 et en équilibrant les signaux le long de l'axe intestin-cerveau ; Petandim for Dogs, un complément destiné à combattre le stress oxydatif chez les chiens ; et Axio, un mélange de boissons énergétiques nootropiques. Elle propose également des produits de soins de la peau anti-âge, tels que du collagène liquide, des nettoyants pour le visage, des crèmes pour les yeux, des crèmes hydratantes, des écrans solaires, des lotions perfectrices et des crèmes pour les mains, ainsi que des shampooings, des revitalisants nourrissants et des sérums pour le cuir chevelu, sous la marque TrueScience.
LifeVantage Corporation Résumé des fondamentaux
| LFVN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$70.77m |
| Bénéfices(TTM) | US$5.75m |
| Recettes(TTM) | US$195.32m |
Le site LFVN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| LFVN compte de résultat (TTM) | |
|---|---|
| Recettes | US$195.32m |
| Coût des recettes | US$42.70m |
| Marge brute | US$152.62m |
| Autres dépenses | US$146.87m |
| Les revenus | US$5.75m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.46 |
| Marge brute | 78.14% |
| Marge bénéficiaire nette | 2.94% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de LFVN?
Voir les performances historiques et les comparaisonsDividendes
Le site LFVN verse-t-il des dividendes fiables ?
Voir LFVN l'historique des dividendes et les indices de référence| LifeVantage dates des dividendes | |
|---|---|
| Date ex-dividende | Jun 01 2026 |
| Date de paiement du dividende | Jun 15 2026 |
| Jours jusqu'au dividende Ex | 5 days |
| Jours jusqu'à la date de paiement du dividende | 19 days |
Le site LFVN verse-t-il des dividendes fiables ?
Voir LFVN l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 00:29 |
| Cours de l'action en fin de journée | 2026/05/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
LifeVantage Corporation est couverte par 5 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |